# Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

> **NCT01477333** · PHASE2 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** UT-15C SR
- **DRUG:** Tyvaso Inhalation Solution

## Key facts

- **NCT ID:** NCT01477333
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01477333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01477333, "Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01477333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*